Pacira BioSciences (PCRX) Cash & Current Investments (2010 - 2026)

Pacira BioSciences' Cash & Current Investments history runs 17 years deep, the most recent figure standing at $202.2 million for Q1 2026.

• In Q1 2026, Cash & Current Investments fell 59.04% year-over-year to $202.2 million; the TTM figure through Mar 2026 stood at $202.2 million (down 59.04% YoY), while the FY2025 annual figure was $238.4 million, down 50.8% from the prior year.
• Cash & Current Investments was $202.2 million for Q1 2026 at Pacira BioSciences, down from $238.4 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $493.6 million in Q1 2025 to a low of $174.0 million in Q1 2023.
• Historically, Cash & Current Investments has averaged $328.8 million across 5 years, with a median of $316.4 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Cash & Current Investments slumped 61.52% in 2023, then jumped 92.96% in 2024.
• A 5-year view of Cash & Current Investments shows it stood at $288.7 million in 2022, then retreated by 3.49% to $278.6 million in 2023, then surged by 73.96% to $484.6 million in 2024, then slumped by 50.8% to $238.4 million in 2025, then slipped by 15.2% to $202.2 million in 2026.
• The last three Cash & Current Investments figures came in at $202.2 million (Q1 2026), $238.4 million (Q4 2025), and $246.3 million (Q3 2025), per Business Quant data.